Lipocine
LPCN
45 hedge funds and large institutions have $109M invested in Lipocine in 2015 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
51% more capital invested
Capital invested by funds: $72.4M → $109M (+$36.9M)
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
18% more funds holding
Funds holding: 38 → 45 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| 1 |
RA
Royce & Associates
New York
|
+$10.2M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$7.11M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$4.68M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$3.18M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$2.35M |
Top Sellers
| 1 |
AC
Armistice Capital
New York
|
-$7.29M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$7.13M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$3M |
| 4 |
VAM
Visium Asset Management
New York
|
-$2.15M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$713K |
LPCN Hedge Fund Activity: Q3 2015 in Review
45 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2015, worth a combined $109M — up 51% from $72.4M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new LPCN positions and 9 closed out — a net gain of 7 holders — while 14 added to existing stakes and 11 trimmed.
The largest buyer was Royce & Associates, adding an estimated $10.2M. The largest seller was Armistice Capital, exiting entirely with an estimated $7.29M sold.
- 45 institutional investors held Lipocine (LPCN) as of Q3 2015, up from 38 in Q2 2015.
- Funds reported $109M of Lipocine stock for Q3 2015, up 51% quarter-over-quarter.
- 16 funds opened new Lipocine positions in Q3 2015 and 9 closed out, a net change of +7 holders.
- The largest Lipocine buyer in Q3 2015 was Royce & Associates, an estimated $10.2M added.
- The largest Lipocine seller in Q3 2015 was Armistice Capital, an estimated $7.29M sold.
Based on aggregated 13F filings for Q3 2015.